Eli Lilly and is strengthening its position in the lucrative weight management sector through a significant $2 billion acquisition of Versanis Bio. This strategic move centers on Bimagrumab, a ...
One participant lost 22% of her weight in nine months — substantially faster than the rate seen with approved GLP-1 drugs ...
Strategic Financial Concepts LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 67.7% during the fourth quarter, according to the company in its most recent filing ...
Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-one brokerages that are presently covering the stock, ...
Eli Lilly and Company's latest 10-K report for the year ended December 31, 2024, reveals significant financial growth. The company reported a revenue of $45,042.7 million, marking a 32% increase from ...
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...
Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.
Current weight-loss methods such as lifestyle changes, surgery, and popular therapies like Novo Nordisk's Wegovy and Eli ...
Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...
President Trump is going scorched earth on America’s major European trading partners. Vowing to impose reciprocal tariffs on ...
Ireland's pharmaceutical industry shipped billions' worth of goods to the U.S., but face threats from Trump 2.0.